Preliminary Results of Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer Accepted for Presentation at Annual American College of Gastroenterology Meeting

The adult findings are preliminary; results from a separate controlled trial are expected in 2027.

Rhea-AI Summary

Jaguar Health (JAGX) announced that an abstract on preliminary adult short bowel syndrome study results was accepted for presentation at ACG 2026. The abstract covers an ongoing open-label study of crofelemer in adults with short bowel syndrome and intestinal failure (SBS-IF). The meeting runs October 9–14, 2026.

Napo Pharmaceuticals is also conducting a controlled Phase 2 trial in adults with Type 1 short bowel syndrome, with results expected early in the second half of 2027. Previously presented pediatric investigations reported reduced weekly parenteral support needs after more than one year of oral liquid crofelemer, with no significant clinical or laboratory abnormalities. Jaguar plans a drug application for microvillus inclusion disease in mid-2027.

Positive

• Minor pointPreliminary adult SBS-IF study results were accepted for presentation at ACG 2026.
• Minor pointPediatric investigations reported reduced weekly parenteral support needs after more than one year of oral treatment.
• Minor pointPediatric investigations reported no significant clinical or laboratory abnormalities.
• Minor point. Forward-looking: it has not happened yet and may not happen.Controlled Phase 2 trial results are expected early in the second half of 2027.
• Minor point. Forward-looking: it has not happened yet and may not happen.Drug application for microvillus inclusion disease is planned for mid-2027.

Negative

• Minor pointAdult SBS-IF findings remain preliminary and come from an ongoing open-label study.

Key Terms

open-label study, phase 2 clinical trial, randomized double-blind placebo-controlled, total parenteral nutrition, +1 more

5 terms

open-label study technical

"preliminary results of an ongoing open-label study"

An open-label study is a type of research where both the participants and the researchers know which treatment or intervention is being administered. This transparency can influence the results, making it important for investors to consider potential biases or limitations when evaluating the study’s findings. Understanding this helps assess the reliability of evidence supporting new products or therapies.

phase 2 clinical trial medical

"randomized double-blind placebo-controlled Phase 2 clinical trial"

A phase 2 clinical trial is a research study that tests a new medical treatment or drug to see if it is effective and safe for a specific condition. It involves a larger group of people than earlier trials and helps determine whether the treatment should move forward to more extensive testing. For investors, successful phase 2 results can signal potential for future approval and commercial success, while setbacks may indicate challenges ahead.

randomized double-blind placebo-controlled technical

"multicenter, randomized double-blind placebo-controlled Phase 2 clinical trial"

A randomized double-blind placebo-controlled trial is a study design that tests a drug or treatment by assigning participants by chance (like flipping a coin) to either the active treatment or an inactive substitute, while keeping both participants and researchers unaware of who has which (like both sides wearing blindfolds). Investors care because this approach produces the most reliable evidence about whether a treatment truly works and is safe, reducing the chance of misleading results that can affect regulatory approval, market value, and commercial prospects.

total parenteral nutrition medical

"require lifelong total parenteral nutrition (TPN)"

Total parenteral nutrition is a medical treatment that supplies all needed calories, fluids, vitamins and minerals directly into a patient’s bloodstream through an IV, bypassing the digestive tract — like a complete meal delivered by a drip. It matters to investors because TPN relies on specialized ingredients, preparation and delivery services with steady hospital and home-care demand, significant regulation and reimbursement exposure, and potential for durable revenue or risk from supply-chain or clinical issues.

new drug application regulatory

"planned New Drug Application (NDA) filing for MVID"

A new drug application is a formal request submitted to government regulators seeking approval to market a new medicine. It is like a detailed proposal that shows the drug has been tested for safety and effectiveness. For investors, receiving approval signals that the drug may soon become available for sale, potentially leading to revenue growth and impacting the company's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN FRANCISCO, CA / ACCESS Newswire / September 29, 2026 / Jaguar Health, Inc. (Nasdaq:JAGX) (Jaguar) family company Napo Pharmaceuticals (Napo) today announced the acceptance of an abstract on preliminary results of an ongoing open-label study of the company's crofelemer powder for oral solution in adult patients with short bowel syndrome with intestinal failure (SBS-IF) for presentation at the American College of Gastroenterology Annual Scientific Meeting (ACG 2026). ACG 2026 takes place October 9-14, 2026 in Nashville, Tennessee.

Napo is conducting a multicenter, randomized double-blind placebo-controlled Phase 2 clinical trial in adult Type 1 short bowel syndrome (SBS) patients without colin-in-continuity. Results from this trial are expected to be available early in the second half of 2027.

Patients with intestinal failure (IF), including those with SBS or MVID, cannot orally absorb adequate nutrients, electrolytes and fluids, and require lifelong total parenteral nutrition (TPN) with or without supplemental intravenous fluids, which together comprise parenteral support (PS), for up to seven days per week and up to 20+ hours per day. While PS is supportive, palliative and lifesaving, it is associated with serious, sometimes fatal complications.

Napo remains sharply focused on its ongoing global development program for oral crofelemer as adjunctive therapy to PS for rare IF diseases, including SBS-IF and MVID. In June 2026, as announced, data was presented at the 58^th Annual European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN) Meeting in Lille, France from ongoing investigational studies with oral liquid crofelemer in pediatric patients with IF due to MVID and SBS-IF. The results of ongoing investigations of liquid oral crofelemer formulations demonstrate substantial reductions in weekly PS needs as well as in PS normalized to body weight in pediatric IF patients dosed orally for more than one year, with no significant clinical or laboratory abnormalities.

Jaguar's IF program is expected to continue to provide clinical milestones, including a planned New Drug Application (NDA) filing for MVID in mid-2027.

About the Jaguar Health Family of Companies

Jaguar Health, Inc. ("Jaguar") develops novel proprietary prescription drugs sustainably derived from plants for people with complicated gastrointestinal ("GI") disease states. Jaguar family companies Napo Pharmaceuticals, Inc. and Napo Therapeutics S.p.A. focus on the development and commercialization of novel crofelemer powder for oral solution for the treatment of rare and orphan gastrointestinal disorders with intestinal failure, including microvillus inclusion disease and short bowel syndrome. Magdalena Biosciences, a joint venture formed by Jaguar and Filament Health Corp. that emerged from Jaguar's Entheogen Therapeutics Initiative (ETI), is focused on developing novel prescription medicines derived from plants for mental health indications.

For more information about:

Jaguar Health, visit https://jaguar.health

Napo Pharmaceuticals, visit napopharma.com

Napo Therapeutics, visit napotherapeutics.com

Magdalena Biosciences, visit magdalenabiosciences.com

Forward-Looking Statements

Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that the company may file an NDA for crofelemer for MVID in mid-2027, and Jaguar's expectation that results from Napo's Phase 2 study of crofelemer in adult Type 1 SBS patients without colin-in-continuity may be available early in the second half of 2027. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. The forward-looking statements in this release are only predictions. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

Contact:
hello@jaguar.health
Jaguar-JAGX

SOURCE: Jaguar Health, Inc.

View the original press release on ACCESS Newswire

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What will Jaguar Health present about crofelemer at ACG 2026?

Jaguar Health will present an abstract on preliminary results from an ongoing open-label study of crofelemer powder for oral solution in adults with short bowel syndrome and intestinal failure. ACG 2026 takes place October 9–14, 2026.